Cargando…
GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL
INTRODUCTION: The SIOP-CNS-GCT-96 trial demonstrated excellent survival for patients with germinoma. Localised patients received either craniospinal irradiation (CSI) 24Gy plus tumour-bed-boost 16 Gy or 2xcarboPEI chemotherapy (carboplatin/etoposide alternating with etoposide/ifosfamide) and focal-r...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715693/ http://dx.doi.org/10.1093/neuonc/noaa222.240 |
_version_ | 1783619014787858432 |
---|---|
author | Bison, Brigitte Morana, Giovanni Mitra, Dipayan Brisse, Herve Faure-Conter, Cecile Ajithkumar, Thankamma Alapetite, Claire Timmermann, Beate Nicholson, James Calaminus, Gabriele Murray, Matthew |
author_facet | Bison, Brigitte Morana, Giovanni Mitra, Dipayan Brisse, Herve Faure-Conter, Cecile Ajithkumar, Thankamma Alapetite, Claire Timmermann, Beate Nicholson, James Calaminus, Gabriele Murray, Matthew |
author_sort | Bison, Brigitte |
collection | PubMed |
description | INTRODUCTION: The SIOP-CNS-GCT-96 trial demonstrated excellent survival for patients with germinoma. Localised patients received either craniospinal irradiation (CSI) 24Gy plus tumour-bed-boost 16 Gy or 2xcarboPEI chemotherapy (carboplatin/etoposide alternating with etoposide/ifosfamide) and focal-radiotherapy 40 Gy. Following trial closure, whole-ventricular-irradiation (WVI) was delivered with focal-radiotherapy to avoid ventricular relapse. Accordingly, current research priorities focus on reducing treatment burden and long-term neurocognitive sequelae. METHODS: SIOP-CNS-GCT-II employed national central radiological review to assess whether dropping the 16Gy boost was safe for localized germinoma in complete-remission (CR) following 2xcarboPEI: i.e. no disease on clinical/marker/radiological assessment. Any abnormal thickening/enhancement after chemotherapy was to be classified as partial-remission (PR). Patients with less than CR after chemotherapy received a boost. RESULTS: Shortly before trial closure (2018), it was noted that national CR rates were discrepant across the largest recruiting countries. For German patients, CR rates were ~80%, compared with ~30–40% for UK and France. A formal neuroradiology review was therefore convened. A total of 59 cases were randomly selected (UK, n=32; France, n=14 and Germany, n=13), including those deemed to be in CR and PR. Cases included those with disease at pituitary, pineal and bifocal sites. Both diagnostic scan and scan after induction chemotherapy were used for assessment. Detailed analysis is ongoing and will be presented. CONCLUSION: Residual changes at both pituitary and pineal sites of uncertain significance may remain after chemotherapy. This process should facilitate consensus to define the best response criteria allowing treatment reduction for CNS germinoma for future clinical trials. |
format | Online Article Text |
id | pubmed-7715693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77156932020-12-09 GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL Bison, Brigitte Morana, Giovanni Mitra, Dipayan Brisse, Herve Faure-Conter, Cecile Ajithkumar, Thankamma Alapetite, Claire Timmermann, Beate Nicholson, James Calaminus, Gabriele Murray, Matthew Neuro Oncol Germ Cell Tumors INTRODUCTION: The SIOP-CNS-GCT-96 trial demonstrated excellent survival for patients with germinoma. Localised patients received either craniospinal irradiation (CSI) 24Gy plus tumour-bed-boost 16 Gy or 2xcarboPEI chemotherapy (carboplatin/etoposide alternating with etoposide/ifosfamide) and focal-radiotherapy 40 Gy. Following trial closure, whole-ventricular-irradiation (WVI) was delivered with focal-radiotherapy to avoid ventricular relapse. Accordingly, current research priorities focus on reducing treatment burden and long-term neurocognitive sequelae. METHODS: SIOP-CNS-GCT-II employed national central radiological review to assess whether dropping the 16Gy boost was safe for localized germinoma in complete-remission (CR) following 2xcarboPEI: i.e. no disease on clinical/marker/radiological assessment. Any abnormal thickening/enhancement after chemotherapy was to be classified as partial-remission (PR). Patients with less than CR after chemotherapy received a boost. RESULTS: Shortly before trial closure (2018), it was noted that national CR rates were discrepant across the largest recruiting countries. For German patients, CR rates were ~80%, compared with ~30–40% for UK and France. A formal neuroradiology review was therefore convened. A total of 59 cases were randomly selected (UK, n=32; France, n=14 and Germany, n=13), including those deemed to be in CR and PR. Cases included those with disease at pituitary, pineal and bifocal sites. Both diagnostic scan and scan after induction chemotherapy were used for assessment. Detailed analysis is ongoing and will be presented. CONCLUSION: Residual changes at both pituitary and pineal sites of uncertain significance may remain after chemotherapy. This process should facilitate consensus to define the best response criteria allowing treatment reduction for CNS germinoma for future clinical trials. Oxford University Press 2020-12-04 /pmc/articles/PMC7715693/ http://dx.doi.org/10.1093/neuonc/noaa222.240 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Germ Cell Tumors Bison, Brigitte Morana, Giovanni Mitra, Dipayan Brisse, Herve Faure-Conter, Cecile Ajithkumar, Thankamma Alapetite, Claire Timmermann, Beate Nicholson, James Calaminus, Gabriele Murray, Matthew GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL |
title | GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL |
title_full | GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL |
title_fullStr | GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL |
title_full_unstemmed | GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL |
title_short | GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL |
title_sort | gct-20. evaluation of neuroradiological response to induction chemotherapy for patients with localised germinoma in the siop cns gct ii trial |
topic | Germ Cell Tumors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715693/ http://dx.doi.org/10.1093/neuonc/noaa222.240 |
work_keys_str_mv | AT bisonbrigitte gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT moranagiovanni gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT mitradipayan gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT brisseherve gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT faurecontercecile gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT ajithkumarthankamma gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT alapetiteclaire gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT timmermannbeate gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT nicholsonjames gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT calaminusgabriele gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial AT murraymatthew gct20evaluationofneuroradiologicalresponsetoinductionchemotherapyforpatientswithlocalisedgerminomainthesiopcnsgctiitrial |